Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 19/20 | 0.52 |
| ▸ | SLC6A4 | P31645 | 19/20 | 0.52 |
| ▸ | SLC6A3 | Q01959 | 19/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 18/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 18/20 | 0.52 |
| ▸ | KCNH2 | Q12809 | 13/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL758733 | 1.00 | SLC6A2 (0.52) | SLC6A2SLC6A4SLC6A3CYP3A4CYP2D6 | |
| Hydrochloric Acid SCHEMBL8369503 | 0.98 | SLC6A2 (0.51) | SLC6A2SLC6A4SLC6A3CYP3A4CYP2D6 | |
| SCHEMBL7313213 | 0.91 | SLC6A2 (0.50) | SLC6A2SLC6A4SLC6A3CYP3A4CYP2D6 | |
| Hydrochloric Acid SCHEMBL7745890 | 0.89 | SLC6A2 (0.49) | SLC6A2SLC6A4SLC6A3CYP3A4CYP2D6 | |
| SCHEMBL6770906 | 0.85 | SLC6A4 (0.53) | SLC6A2SLC6A4SLC6A3CYP3A4CYP2D6 | |
| SCHEMBL6604805 | 0.84 | SLC6A2 (0.40) | SLC6A2SLC6A4SLC6A3CYP3A4CYP2D6 | |
| SCHEMBL6604797 | 0.84 | SLC6A2 (0.40) | SLC6A2SLC6A4SLC6A3CYP3A4CYP2D6 | |
| SCHEMBL7666332 | 0.81 | SLC6A4 (0.47) | SLC6A2SLC6A4SLC6A3CYP3A4CYP2D6 | |
| SCHEMBL6770177 | 0.81 | SLC6A2 (0.51) | SLC6A2SLC6A4SLC6A3CYP3A4CYP2D6 | |
| SCHEMBL5866353 | 0.80 | MCHR1 (0.44) | SLC6A2SLC6A4SLC6A3CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 80 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7368461-B2 | Compounds and method for the treatment of overactive bladder | ASTRAZENECA AB (SE) | 2008-05-06 | — | — | US | disclosed |
| EP-1444220-B1 | COMPOUNDS AND METHOD FOR THE TREATMENT OF OVERACTIVE BLADDER | ASTRAZENECA AB (SE) | 2007-02-14 | — | — | EP | disclosed |
| US-7053213-B2 | Therapeutic heterocycles | ASTRAZENECA AB (SE) | 2006-05-30 | — | — | US | disclosed |
| US-6963011-B2 | N-(2-phenyl-3-aminopropyl)naphthamides | ASTRAZENECA AB (SE) | 2005-11-08 | — | — | US | disclosed |
| EP-1278719-B1 | NAPHTHAMIDE NEUROKININ ANTAGONISTS FOR USE AS MEDICAMENTS | ASTRAZENECA AB (SE) | 2005-11-02 | — | — | EP | disclosed |
| US-20050203113-A1 | Compounds and method for the treatment of overactive bladder | ASTRAZENECA AB (SE) | 2005-09-15 | — | — | US | disclosed |
| US-6903092-B2 | Naphthamide neurokinin antagonists for use as medicaments | ASTRAZENECA AB (SE) | 2005-06-07 | — | — | US | disclosed |
| EP-1307425-B1 | NOVEL N-(2-PHENYL-3-AMINOPROPYL)NAPHTAMIDES | ASTRAZENECA AB (SE) | 2005-04-20 | — | — | EP | disclosed |
| EP-1119551-B1 | NAPHTHALENECARBOXAMIDES AS TACHYKININ RECEPTOR ANTAGONISTS | ASTRAZENECA AB (SE) | 2004-12-29 | — | — | EP | disclosed |
| US-20040248914-A1 | Method for the treatment of overactive bladder | ASTRAZENECA AB (SE) | 2004-12-09 | — | — | US | disclosed |
| EP-0700387-A1 | SALTS OF SUBSTITUTED HETEROAROMATIC NITROGEN COMPOUNDS, METHOD FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOUNDS CONTAINING SAME | SANOFI (FR) | 1996-03-13 | — | — | EP | disclosed |
| WO-1995026339-A1 | SALTS OF SUBSTITUTED HETEROAROMATIC NITROGEN COMPOUNDS, METHOD FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOUNDS CONTAINING SAME | SANOFI (FR) | 1995-10-05 | — | — | WO | disclosed |
| EP-0667858-A1 | 4-CARBOXOAMIDO PIPERIDINE DERIVATIVES, INTERMEDIATES AND USE AS NEUROKININ ANTAGONISTS | ZENECA LIMITED (GB) | 1995-08-23 | — | — | EP | disclosed |
| WO-1995015961-A1 | BICYCLIC HETEROCYCLES AS NEUROKININ A ANTAGONISTS | ZENECA LIMITED (GB) | 1995-06-15 | — | — | WO | disclosed |
| WO-1995012577-A1 | NOVEL 4-PIPERIDINYL SUBSTITUTED LACTAMES AS NEUROKININ 2 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF ASTHMA | ZENECA LIMITED (GB) | 1995-05-11 | — | — | WO | disclosed |
| WO-1995005377-A1 | HETEROCYCLES USEFUL AS NEUROKININ ANTAGONISTS | ZENECA LIMITED (GB) | 1995-02-23 | — | — | WO | disclosed |
| EP-0625509-A1 | N-alkyl substituted piperidine-derivatives with neurokinin receptor antagonist activity | ZENECA LIMITED (GB) | 1994-11-23 | — | — | EP | disclosed |
| WO-1994010146-A1 | 4-CARBOXOAMIDO PIPERIDINE DERIVATIVES, INTERMEDIATES AND USE AS NEUROKININ ANTAGONISTS | ZENECA LIMITED (GB) | 1994-05-11 | — | — | WO | disclosed |
| WO-1993018002-A1 | QUATERNARY SALTS OF 4-SUBSTITUTED PIPERIDINES, PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | ELF SANOFI (FR) | 1993-09-16 | — | — | WO | disclosed |
| EP-0559538-A1 | Quaternary salts of 4-substituted piperidines, their preparation and pharmaceutical compositions containing them | SANOFI (FR) | 1993-09-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040248914-A1 | Method for the treatment of overactive bladder | TACR1, TACR2, OGFR | SLC6A2 329/4885SLC6A4 527/4885SLC6A3 304/4885 |
| US-20050203113-A1 | Compounds and method for the treatment of overactive bladder | TACR1, TACR2, BDKRB1 | SLC6A2 275/4885SLC6A4 617/4885SLC6A3 151/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.